DeutschNewstral
Article
Bbarrons.com on 2021-01-29 16:42
The FDA Delayed Its Decision on Biogen’s Alzheimer’s Drug. The Stock Is Up 10%.
Related news
FDA approves Biogen’s controversial Alzheimer’s drugNew York Post- MSigns point to FDA approval for Biogen’s experimental Alzheimer’s disease treatment, though there are skepticsmarketwatch.com
- BSigns Point to FDA Approval for Biogen’s Alzheimer’s Drugbarrons.com
- BBiogen Stock Gains Before Anticipated FDA Decisionbarrons.com
What Is Donanemab? Eli Lilly’s Alzheimer’s Drug Gets Delayed Decision From FDAForbes- BBiogen’s Alzheimer’s Drug Won’t Get Approved, Analyst Saysbarrons.com
- MBiogen’s FDA-approved Alzheimer’s drug, first new remedy in almost twenty yearsmvtelegraph.com
FDA approves Biogen’s Alzheimer’s drug, the first to slow the diseasewsj.com
Biogen’s Alzheimer’s drug isn't FDA-approved yet, but it may already have a namebizjournals.com- MBiogen’s stock blasts off after surprise reversal on Alzheimer’s drug, earnings beatmarketwatch.com
- BBiogen Stock Is Soaring as Hope Returns for Alzheimer’s Drugbarrons.com
- BBiogen’s Alzheimer’s Drug Inches Closer to Approval. That Doesn’t Make the Stock a Buy.barrons.com
- BAfter Lengthy Delay, Biogen Submits Troubled Alzheimer’s Drug for FDA Approvalbarrons.com
- MThird member of the celebrated FDA panel resigns as a result of approval of Biogen’s Alzheimer’s drugmvtelegraph.com
- BBiogen’s Alzheimer’s Drug Could Be a Winner. One Analyst Recommends the Bet.barrons.com
- MBiogen’s key Alzheimer’s disease drug is facing potential signs of troublemarketwatch.com
A “disgraceful decision:” Researchers blast FDA for approving Alzheimer’s drugArs Technica- FBiogen’s Alzheimer’s drug shows early promiseft.com